The rating was downgraded by Oppenheimer to "Perform" on Tuesday, April 26. As per Wednesday, November 30, the company rating was upgraded by Kepler Cheuvreux. The firm has "Neutral" rating by Credit Suisse given on Thursday, March 17. The company was upgraded on Saturday, October 15 by Bernstein. The stock has "Equal-Weight" rating by Morgan Stanley on Wednesday, January 4. JP Morgan has "Neutral" rating and €161 target. Eagle Asset Mngmt, a Florida-based fund reported 592,172 shares. The firm has "Buy" rating by Equinet given on Tuesday, May 3. Piper Jaffray Companies' price objective points to a potential upside of 21.57% from the company's current price.
Sabby Management Llc increased Sarepta Therapeutics Inc (SRPT) stake by 275.7% reported in 2016Q4 SEC filing. About 1.29M shares traded. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) has "Overweight" rating given on Monday, September 19 by PiperJaffray. It has outperformed by 80.12% the S&P500.The move comes after 6 months negative chart setup for the $1.92B company. It was reported on Jun, 23 by Barchart.com. (SRPT) opened at 35.37 on Thursday.
Sarepta Therapeutics, Inc.is a biopharmaceutical company. The company has market cap of $104.80 million. The Firm focuses on the discovery and development of ribose nucleic acid -targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). Emerald Mutual Fund Advisers reported 0.53% in Sarepta Therapeutics Inc (NASDAQ:SRPT). They expect $-0.91 earnings per share, up 32.09% or $0.43 from last year's $-1.34 per share.
Among 24 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 16 have Buy rating, 1 Sell and 7 Hold. Previously Sarepta Therapeutics (NASDAQ:SRPT) reported $1.5 earnings per share (EPS) for the quarter, beating the consensus estimate of $-0.32 by $1.82 with surprise factor of 568.8%. Therefore 67% are positive. Tenaris SA had 26 analyst reports since August 5, 2015 according to SRatingsIntel. The company was maintained on Friday, December 16 by RBC Capital Markets. The rating was maintained by Roth Capital with "Buy" on Thursday, August 20. Finally, Royal Bank Of Canada cut their price objective on Sarepta Therapeutics from $98.00 to $91.00 and set an "outperform" rating on the stock in a research report on Wednesday, March 1st. The firm has "Buy" rating by Citigroup given on Monday, October 5.
Investors sentiment decreased to 1.25 in Q4 2016.
Breaking with tradition, Trump White House forgoes Ramadan dinner
The end of the Ramadan month is announced based on the sighting of the new moon and it varies from one country to another country. Official Twitter for Haramain, which gives updates about Makkah and Madinah, announced the sighting of the moon on Saturday.
Beta is also an important valuation ratio for analyzing the stock of the company, SRPT has Beta of 1.21 while its industry and Sector's beta remains at 0.97 and 0.87 respectively. It worsened, as 42 investors sold Sarepta Therapeutics Inc shares while 46 reduced holdings. 22 funds opened positions while 45 raised stakes. Sarepta Therapeutics Inc (NASDAQ:SRPT) has risen 96.82% since June 23, 2016 and is uptrending. Blackrock Limited Liability Company holds 0.03% or 938,370 shares. Baird Financial Group Inc. acquired a new position in shares of Sarepta Therapeutics during the first quarter valued at approximately $223,000. Raymond James Serv Advisors Incorporated holds 0% or 8,063 shares. The target implies a 76.62% spike from where the shares are now trading. Geduld E E has invested 0.17% in Sarepta Therapeutics Inc (NASDAQ:SRPT). The hedge fund run by Thomas Bancroft held 5.95M shares of the catalog and specialty distribution company at the end of 2016Q4, valued at $118.81 million, up from 5.88M at the end of the previous reported quarter. Quantitative Ltd Liability Co invested in 197,400 shares. Decatur Cap Management owns 133,359 shares or 2.2% of their USA portfolio. Blackrock Group has invested 0.01% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT). Geode Cap Ltd Llc has 0% invested in Echo Global Logistics, Inc.
Since January 1, 0001, it had 3 insider buys, and 1 sale for $ activity. JMP Securities lowered their target price on Sarepta Therapeutics to $48.00 in a research note on Wednesday, March 1st. Shares for $18.75 million were sold by Zuckerberg Mark on Friday, June 9. Wendels Amelie sold 225 shares worth $23,634. On Sunday, February 19 the insider Fredin Steven R sold $100,702.
Investors sentiment is 0.86 in Q4 2016. Its the same as in 2016Q3. It fall, as 69 investors sold JPM shares while 807 reduced holdings. Venbio Select Advisor Ltd reported 1.01 million shares stake. (NYSE:JPM). Moreover, First Foundation has 0.05% invested in JPMorgan Chase & Co. Pnc Svcs Grp Inc has invested 0% in Allianz SE (ETR:ALV). Eqis Capital Mgmt holds 5,420 shares. 28,955 are owned by Century Cap Management Ltd Liability. Apg Asset Mngmt Us Inc holds 0.94% or 2.21 million shares. Marketfield Asset Management Ltd Liability Company invested 1.56% of its portfolio in Facebook Inc (NASDAQ:FB). Creative Planning owns 99,325 shares or 0.02% of their United States portfolio. Leavell Inv Mngmt has invested 0.08% in Bank of New York Mellon Corp (NYSE:BK). The Company's divisions include Office and Other.
About 158,603 shares traded. Tenaris SA (ADR) (NYSE:TS) has risen 25.06% since June 23, 2016 and is uptrending.
Comments